Evaluation effect of empaglifulazin on depression in patients with heart failure with reduced ejection fraction: a randomizd clincal trial

Abstract

Introduction: Cardiovascular diseases are one of the top 5 causes of death in the world today. So far, despite numerous clinical trials, no cure has been found for acute heart failure. The only way to treat heart failure is to control it with medications. There is a bidirectional relationship between depression and cardiovascular disease. Although the empagliflozin is part of the common treatment protocol for cardiovascular patients, the effect of empagliflozin on depression in patients with heart failure with reduced ejection fraction has not been evaluated. The present study was presented to investigate and compare whether doses of 10 and 25 mg of Empagliflozin affect depression or not. Objectives: In this study, the main purpose was to investigate and compare the Hamilton score of patients using empagliflozin with doses of 10 and 25 mg.Methods: This study was performed as a randomized trial in Shahid Madani Heart Hospital of Tabriz University of Medical Sciences. 76 patients with conditions were randomly assigned into two groups of 38 and 36 (empagliflozin 10 mg and empagliflozin 25 mg). Changes in Hamilton score were evaluated in three months. Results: The results showed that there was a significant change in the Hamilton score of the patients taking doses of 10 mg and 25 mg of empagliflozin in the first month, but there was no significant change in the data in the third month. Conclusion: In this study, it can be concluded that the doses of 10 mg and 25 mg of empagliflozin had the same effect on depression in heart failure patients with reduced ejection fraction.